ConductScience.org, home

Library / Trial comparisons

With Antihypertensive vs Without Antihypertensive: Number of Participants With Treatment-Related Adverse Events: With/Without Concomitant Drug (Antihypertensive)

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measures 6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNoteSource
Risk in group 10.01740.01470.0205wilsonClinicalTrials.gov
Risk in group 20.01310.01040.0164wilsonClinicalTrials.gov
Risk difference, group 1 minus group 20.004290.000005150.00842newcombe hybrid scoreClinicalTrials.gov
Risk ratio, group 1 over group 21.3311.76logClinicalTrials.gov
Odds ratio, group 1 over group 21.3311.78logClinicalTrials.gov
Number needed to treat, for one more participant with the outcome on With Antihypertensive than on Without Antihypertensive233119194,000from the risk difference intervalClinicalTrials.gov

Groups 2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov codeSource
Group 1With Antihypertensive
Participants who received antihypertensive as a concomitant drug and experienced treatment-related adverse events after having received Amlodipine Tablets or Amlodipine OD Tablets 10 mg/day orally according to Japanese Package Insert at least once.
1367,834OG000ClinicalTrials.gov
Group 2Without Antihypertensive
Participants who received no antihypertensive as a concomitant drug and experienced treatment-related adverse events after having received Amlodipine Tablets or Amlodipine OD Tablets 10 mg/day orally according to Japanese Package Insert at least once.
725,509OG001ClinicalTrials.gov

Outcome 5

FieldValueSource
TypeSECONDARYClinicalTrials.gov
TitleNumber of Participants With Treatment-Related Adverse Events: With/Without Concomitant Drug (Antihypertensive)ClinicalTrials.gov
DescriptionTo determine whether receiving antihypertensive as a concomitant drug was a significant risk factor likely to affect the frequency of treatment-related adverse events.ClinicalTrials.gov
Time frameLast day of observation period (average of 14.76 weeks)ClinicalTrials.gov
PopulationThe safety analysis population comprised participants who had taken Amlodipine Tablets or Amlodipine OD Tablets at 10 mg/day at least once after the start of treatment.ClinicalTrials.gov

Trial 8

FieldValueSource
TitleAmlodipine 10mg Drug Use InvestigationClinicalTrials.gov
NCT numberNCT01252563ClinicalTrials.gov
PhasesClinicalTrials.gov
ConditionsHypertensionClinicalTrials.gov
InterventionsAmlodipineClinicalTrials.gov
Lead sponsorPfizer's Upjohn has merged with Mylan to form Viatris Inc.ClinicalTrials.gov
Results first posted2019-04-02ClinicalTrials.gov
Results on ClinicalTrials.govhttps://clinicaltrials.gov/study/NCT01252563?tab=resultsClinicalTrials.gov

Source 4

FieldValueSource
Releasetrial-comparisons-2026-03-23-0.1.0ClinicalTrials.gov
Release manifest SHA-256f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57ClinicalTrials.gov
AACT copy2026-03-23ClinicalTrials.gov
Tables readoutcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquetClinicalTrials.gov

The same record as JSON

Release trial-comparisons-2026-03-23-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.